Cargando…
Will the antimalarial drug take over to combat COVID-19?
BACKGROUND: China has been fighting the epidemic of pneumonia-like diseases first detected for over a month in the city of Wuhan in December 2019. The disease epidemic is caused by a novel coronavirus, called COVID-19, which has now infected more than 700,000 people worldwide. With a death toll appr...
Autores principales: | T.K, Sivabakya, G, Srinivas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189021/ https://www.ncbi.nlm.nih.gov/pubmed/32351873 http://dx.doi.org/10.1007/s10389-020-01293-0 |
Ejemplares similares
-
Lung Barrier Function in COVID-19?
por: Sivabakya, T. K., et al.
Publicado: (2020) -
Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery
por: Shibeshi, Melkamu Adigo, et al.
Publicado: (2020) -
Repurposing antimalarials and other drugs for COVID-19
por: Schlagenhauf, Patricia, et al.
Publicado: (2020) -
Antimalarials as Antivirals for COVID-19: Believe it or Not!
por: Saha, Biplab K., et al.
Publicado: (2020) -
World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
por: Price, Ric N, et al.
Publicado: (2007)